Financial health
- Operating income covered interest expense -735.7× in the latest year.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$26M | — | — | — | — | $10M |
| 2024 | — | -$5M | — | — | -$25M | — | $862089 |
| 2023 | — | -$20M | — | — | — | — | $21M |
| 2022 | — | -$27M | — | — | — | — | $41M |
| 2021 | — | -$14M | — | — | — | — | $57M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Apr '26 | — | -$7M | — | — | — | — | $7M |
| Jan '26 | — | -$7M | — | — | — | — | $30M |
| Oct '25 | — | -$8M | — | — | — | — | $3M |
| Jul '25 | — | -$8M | — | — | — | — | $10M |
| Apr '25 | — | -$6M | — | — | — | — | $12M |
| Jan '25 | — | -$6M | — | — | — | — | $5M |
| Oct '24 | — | -$6M | — | — | — | — | $6M |
| Jul '24 | — | -$1M | — | — | — | — | $862089 |
| Apr '24 | — | $2M | — | — | — | — | $935694 |
| Jan '24 | — | -$11M | — | — | — | — | $6M |
| Oct '23 | — | $6M | — | — | — | — | $14M |
| Jul '23 | — | -$2M | — | — | — | — | $21M |
| Apr '23 | — | -$5M | — | — | — | — | $28M |
| Jan '23 | — | -$12M | — | — | — | — | $34M |
| Oct '22 | — | -$1M | — | — | — | — | $37M |
| Jul '22 | — | -$450352 | — | — | — | — | $41M |
| Apr '22 | — | -$10M | — | — | — | — | — |
| Jan '22 | — | $11M | — | — | — | — | — |
| Oct '21 | — | -$28M | — | — | — | — | — |
See the revenue and net-income charts above for BriaCell Therapeutics Corp.'s multi-year trend.
As of FY2025, BriaCell Therapeutics Corp. reported — of total debt against $10M of cash; operating income covered interest expense -735.7×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.